Get the Stockscreener App
26.49
5.16%
-1.44
After Hours:
26.45
-0.04
-0.15%
Alkermes Plc stock is traded at $26.49, with a volume of 2.23M.
It is down -5.16% in the last 24 hours and down -7.41% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$27.93
Open:
$27.49
24h Volume:
2.23M
Relative Volume:
1.22
Market Cap:
$4.37B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
13.58
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-0.15%
1M Performance:
-7.41%
6M Performance:
-15.98%
1Y Performance:
-3.04%
1-Day Range:
$26.35
$27.62
1-Week Range:
$25.71
$28.67
52-Week Range:
$25.56
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
26.49 | 4.61B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Alkermes shares climb 5% following Q2 earnings and revenue beat - MSN
(07/31/25) ALKS: Positive Narcolepsy Drug Trial Puts this Biotech Name in F - moneyshow.com
Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances - MSN
Alkermes: A More Than Solid Quarter (NASDAQ:ALKS) - Seeking Alpha
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - Zacks Investment Research
Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript - Insider Monkey
Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS) - MarketBeat
Schizophrenia Drugs Market Exclusive Report with Detailed - openPR.com
Alkermes PLC (ALKS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Alkermes Reports Strong Q2 2025 Financial Results - TipRanks
Alkermes Beat Expectations With A Strong Second Quarter - Finimize
Trading Bots Trigger Alerts on Alkermes plc ActivityDaily Smart Money Movement Monitor Activated - metal.it
Multi Factor Analysis Ranks Alkermes plc as Strong BuyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Alkermes Earnings Call: Strong Growth and Promising Trials - TipRanks
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire
Alkermes price target lowered to $33 from $35 at BofA - TipRanks
Why Alkermes plc stock attracts strong analyst attentionScalable Portfolio Growth Suggestions Released - metal.it
Published on: 2025-07-29 17:34:19 - metal.it
Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Alkermes plc. SEC 10-Q Report - TradingView
Alkermes Q2 Sales Up 14 Percent - The Globe and Mail
Alkermes: Q2 Earnings Snapshot - The Washington Post
Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Alkermes Q2 Earnings Exceed Expectations with Impressive Financial PerformanceNews and Statistics - IndexBox
Alkermes reports Q2 EPS 52c, consensus 38c - TipRanks
Alkermes Plc earnings beat by $0.16, revenue topped estimates - Investing.com Canada
Alkermes shares rise 5% as Q2 earnings, revenue beat expectations By Investing.com - Investing.com South Africa
Alkermes plc Reports Second Quarter 2025 Financial Results - PR Newswire
RSI and MACD Indicate Shift in Alkermes plc SentimentStock Selection With High Accuracy Based on Models - metal.it
Alkermes plc Forms Double Bottom Pattern — Eyes on BreakoutInvestment Strategy With Predictable Gains Outlined - metal.it
Does Alkermes plc stock perform well during market downturnsEntry Signal Watchlist With High Returns - jammulinksnews.com
Federal Circuit Finds No Jurisdiction Over Patent Royalty Row, Transfers Case - Law360
Alkermes PLC (ALKS) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Is Alkermes plc stock overvalued or undervaluedAchieve consistent profits with expert advice - jammulinksnews.com
Should I hold or sell Alkermes plc stock in 2025Identify breakout stocks before they peak - jammulinksnews.com
What are analysts’ price targets for Alkermes plc in the next 12 monthsFree Market Volatility Navigation Tips - jammulinksnews.com
Is Alkermes plc Stock Overbought or Oversold RSI Indicator AnalysisCapital Efficient Investment Tips - metal.it
How does Alkermes plc generate profit in a changing economyUnlock exclusive stock analysis for investors - jammulinksnews.com
What catalysts could drive Alkermes plc stock higher in 2025Phenomenal trading returns - jammulinksnews.com
Is Alkermes plc a growth stock or a value stockUnlock steady growth with low-risk stocks - jammulinksnews.com
What drives Alkermes plc stock priceSuperior capital gains - Autocar Professional
Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN
Abivax’s miRNA therapy emerges as a new mechanism for ulcerative colitis - BioCentury
Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating - MSN
What analysts say about Alkermes plc stockHigh-yield portfolio picks - Autocar Professional
Alkermes plc Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com
Is Alkermes plc a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):